ABCL | Ticker Profile - Titan Protect

ABCL

AbCellera Biologics Inc.

Healthcare · Biotechnology · NMS

$5.62

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.56

Based on estimated future earnings — lower means cheaper

Rev Growth

+96.3%

Year-over-year revenue change

Profit Margin

-181.7%

How much profit the company keeps from each dollar of revenue

ROE

-14.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+96% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

https://www.abcellera.com

Country: Canada Employees: 562 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.592

Good returns relative to risk taken

Kelly Fraction

0.0265

Modest edge detected — smaller position warranted

Calmar Ratio

0.339

Drawdown risk outweighs the returns — higher risk profile

Annual Return

18.6%

Historical annualised return based on price data

Max Drawdown

-54.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$6.52

14% below the year high

52W Low

$1.98

184% above the year low

Avg Volume

5,621,008

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

18.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

14.32

Heavy leverage — higher financial risk if revenues decline

Current Ratio

14.05

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

11.45

Like current ratio but excludes inventory — stricter test

Gross Margin

-135.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-691.8%

Profit from core operations before interest and tax

Free Cash Flow

$-105,397,248

Negative — the business is spending more than it generates

Revenue (TTM)

$79M

Total revenue over the last 12 months

Net Income

$-143,956,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$13.00

Target Median

$11.00

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go